Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/29197
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDudreuilh, C-
dc.contributor.authorBasu, S-
dc.contributor.authorScottà, C-
dc.contributor.authorDorling, A-
dc.contributor.authorLombardi, G-
dc.date.accessioned2024-06-16T12:22:52Z-
dc.date.available2024-06-16T12:22:52Z-
dc.date.issued2021-02-02-
dc.identifierORCiD: Cristiano Scottá https://orcid.org/0000-0003-3942-5201-
dc.identifier.citationDudreuilh, C. et al. (2021) 'Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation', Frontiers in Immunology, 11, 612848, pp. 1 - 18. doi: 10.3389/fimmu.2020.612848.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/29197-
dc.description.abstractRegulatory T cells (Tregs) constitute a small proportion of circulating CD4+ T cells that function to maintain homeostasis and prevent autoimmunity. In light of their powerful immunosuppressive and tolerance-promoting properties, Tregs have become an interesting potential candidate for therapeutic use in conditions such as solid organ transplant or to treat autoimmune and inflammatory conditions. Clinical studies have demonstrated the safety of polyclonally expanded Tregs in graft-versus-host disease, type 1 diabetes, and more recently in renal and liver transplantation. However, Tregs are heterogenous. Recent insights indicate that only a small proportion of Tregs, called T follicular regulatory cells (Tfr) regulate interactions between B cells and T follicular helper (Tfh) cells within the germinal center. Tfr have been mainly described in mouse models due to the challenges of sampling secondary lymphoid organs in humans. However, emerging human studies, characterize Tfr as being CD4+CD25+FOXP3+CXCR5+ cells with different levels of PD-1 and ICOS expression depending on their localization, in the blood or the germinal center. The exact role they play in transplantation remains to be elucidated. However, given the potential ability of these cells to modulate antibody responses to allo-antigens, there is great interest in exploring translational applications in situations where B cell responses need to be regulated. Here, we review the current knowledge of Tfr and the role they play focusing on human diseases and transplantation. We also discuss the potential future applications of Tfr therapy in transplantation and examine the evidence for a role of Tfr in antibody production, acute and chronic rejection and tertiary lymphoid organs. Furthermore, the potential impact of immunosuppression on Tfr will be explored. Based on preclinical research, we will analyse the rationale of Tfr therapy in solid organ transplantation and summarize the different challenges to be overcome before Tfr therapy can be implemented into clinical practice.en_US
dc.description.sponsorshipThe authors have received funding from the Medical Research Council (MRC): award number MR/S000852/1 for CD and MR/T006560/1 for SB. This work was further supported by the Department of Health (DoH) via the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre award to King’s Health Partners. Institutional Open Access funds to support article publication were also received.en_US
dc.format.medium1 - 18-
dc.format.mediumElectronic-
dc.language.isoen_USen_US
dc.publisherFrontiers Mediaen_US
dc.rightsCopyright © 2021 Dudreuilh, Basu, Scottà, Dorling and Lombardi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectregulatory T cellen_US
dc.subjectT-follicular regulatory cellen_US
dc.subjecttransplantationen_US
dc.subjectcell therapyen_US
dc.subjectimmunosuppressionen_US
dc.titlePotential Application of T-Follicular Regulatory Cell Therapy in Transplantationen_US
dc.typeArticleen_US
dc.date.dateAccepted2020-12-14-
dc.identifier.doihttps://doi.org/10.3389/fimmu.2020.612848-
dc.relation.isPartOfFrontiers in Immunology-
pubs.publication-statusPublished-
pubs.volume11-
dc.identifier.eissn1664-3224-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dc.rights.holderDudreuilh, Basu, Scottà, Dorling and Lombardi-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2021 Dudreuilh, Basu, Scottà, Dorling and Lombardi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.1.21 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons